Search
BRD-810
go.drugbank.com/drugs/DB23607ExperimentalBRD-810 is an experimental small molecule being investigated as a potential anti-cancer medication. It is an inhibitor of the protein myeloid cell leukemia 1 (MCL1). [A274263]
Influenza B virus B/Michigan/01/2021 antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB16917ApprovedUpon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus. … These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen
Imiquimod
go.drugbank.com/drugs/DB00724ApprovedInvestigationalImiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas.
International brands: Li Di, Nan BoCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesLevamlodipine
go.drugbank.com/drugs/DB09237ApprovedInvestigationalLevamlodipine, also known as S-amlodipine, is a pharmacologically active enantiomer of [amlodipine], an antihypertensive medication.
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesGuselkumab
go.drugbank.com/drugs/DB11834ApprovedInvestigationalIL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation [A20357].
Nomifensine
go.drugbank.com/drugs/DB04821ApprovedWithdrawnNomifensine, formerly marketed as Merital capsules, was associated with an increased incidence of hemolytic anemia.
Synonyms: D,L-nomifensineSea salt
go.drugbank.com/drugs/DB11266ApprovedUnlike sea salt, table salt usually contains an additive to prevent clumping and involves addition of iodine.
Products: Ruby Cell 4u Mud Moisture PureEmicizumab
go.drugbank.com/drugs/DB13923ApprovedInvestigationalEmicizumab was originated as an improved form of hBS23 and it was approved on November 16, 2017.[A31279, L1016] It was created by Chugai Pharmaceuticals Co.
Clesrovimab
go.drugbank.com/drugs/DB18877ApprovedInvestigationalpatients, nor are vaccines immediately effective in this population, clesrovimab and similar monoclonal antibodies like [nirsevimab] are designed to provide passive immunization against RSV infection as an